Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Leticia Madalena is active.

Publication


Featured researches published by Leticia Madalena.


Clinical Chemistry and Laboratory Medicine | 2010

Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience.

Mariel Emilce Alejandre; Leticia Madalena; Miguel A. Pavlovsky; María Laura Facio; Claudia Corrado; Gustavo Milone; Pablo Bresciani; Susana Fraind; Santiago Pavlovsky; Marco Pizzolato

Abstract Background: Over the last 20 years, high dose therapy followed by hemopoietic stem cell transplantation has been employed in patients with multiple myeloma (MM). During 16 years of follow-up, the degree of tumor response and survival in 238 patients with autologous stem cell transplantation (ASCT) and changes in the serum protein electrophoretic pattern were analyzed. Methods: Agarose gel electrophoresis with densitometric analysis and immunofixation were performed to evaluate serum monoclonal protein. IgM, IgA, IgG and β2-microglobulin (β2M) were quantitated. Urine protein electrophoresis with IF was performed on cellulose acetate gel using colloidal silver staining without concentrating. Results: After 34 months of follow-up (range 1–160 months), eight patients (3.4%) showed a distinct monoclonal protein band that was different from their original isotype switch. This was observed to be a transient phenomenon (22.2 months). Thirty-seven patients (15.5%) developed oligoclonal bands (OB) between the first and the twentieth month after ASCT (mean 4.4 months), which persisted for 7.9 months (1–36 months). The mean overall survival time was statistically different (p<0.05) between the group with OB and the group without them. Mean values of serum albumin, β2M, and non-involved immunoglobulins did not show statistical differences. Conclusions: The occurrence of OB could be a potential favorable prognostic marker after transplantation due to the prolonged survival observed. Close follow-up of anomalous protein bands, either in serum or urine, is essential due to the additional difficulty in interpretation when the therapeutic response and evolution are evaluated. Clin Chem Lab Med 2010;48:727–31.


International Journal of Nephrology | 2012

Understanding the Mechanisms of Proteinuria: Therapeutic Implications

Jorge E. Toblli; P. Bevione; F. Di Gennaro; Leticia Madalena; Gabriel Cao; Margarita Angerosa

A large body of evidence indicates that proteinuria is a strong predictor of morbidity, a cause of inflammation, oxidative stress and progression of chronic kidney disease, and development of cardiovascular disease. The processes that lead to proteinuria are complex and involve factors such as glomerular hemodynamic, tubular absorption, and diffusion gradients. Alterations in various different molecular pathways and interactions may lead to the identical clinical end points of proteinuria and chronic kidney disease. Glomerular diseases include a wide range of immune and nonimmune insults that may target and thus damage some components of the glomerular filtration barrier. In many of these conditions, the renal visceral epithelial cell (podocyte) responds to injury along defined pathways, which may explain the resultant clinical and histological changes. The recent discovery of the molecular components of the slit diaphragm, specialized structure of podocyte-podocyte interaction, has been a major breakthrough in understanding the crucial role of the epithelial layer of the glomerular barrier and the pathogenesis of proteinuria. This paper provides an overview and update on the structure and function of the glomerular filtration barrier and the pathogenesis of proteinuria, highlighting the role of the podocyte in this setting. In addition, current antiproteinuric therapeutic approaches are briefly commented.


Clinical Chemistry and Laboratory Medicine | 2012

Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation.

Mariel Emilce Alejandre; Miguel A. Pavlovsky; Guillermina Remaggi; Claudia Corrado; Isolda Fernandez; Gustavo Milone; Astrid Pavlovsky; Leticia Madalena; Marcela Pandolfo; María Laura Facio; Pablo Bresciani; Santiago Pavlovsky; Marco Pizzolato

Abstract Background: To establish stringent complete remission (SCR) in patients with multiple myeloma (MM), it is currently recommended to obtain a normal serum free light chains (sFLC) ratio. The appearance of serum oligoclonal bands (OB) after autologous stem cell transplantation (ASCT) is considered a favorable prognostic factor. The objective of this study was to examine sFLC for assessing SCR in patients with MM, and ASCT with OB. We also examined how capillary electrophoresis (CE) compares with agarose gel electrophoresis (Aga) in identifying oligoclonal bands. Methods: Out of 238 patients studied in our institution between April 1992 and December 2008 a serum protein electrophoresis (SPE) was performed by means of CE and sFLC determination on 37 patients with MM in complete remission (CR), ASCT and OB presence were assigned by conventional Aga electrophoresis and IF. Results: Statistically significant differences (SSD) were found when comparing CE vs. Aga, regarding BO visualization in SPE, favoring the latter. In connection with sFLC, the group of patients with an abnormal ratio presented elevated values in the γ-globulin zone of the SPE, whereas the group of patients with a normal ratio of sFLC presented with normal values resulting in SSD between the groups. Conclusions: It is essential to perform immunofixation to certify the presence of OB, especially if CE is used as it is difficult to distinguish them using this method. A normal sFLC was observed in most of the patients with OB and normal values of the SPE γ-globulin zone. The above-mentioned information might demonstrate a limitation of sFLC test in SCR evaluation for patients with MM, ASCT and CR if OB has been detected.


Acta Bioquimica Clinica Latinoamericana | 1996

Electroinmunofijación de orinas sin concentrar por coloración con metales pesados

Marcelo García; Leticia Madalena; Marco Pizzolato; Pablo Bresciani; Gabriel C Bragantini


Acta Bioquimica Clinica Latinoamericana | 2010

Seguimiento del perfil proteico urinario en el trasplante renal

María Laura Facio; Leticia Madalena; María del Carmen Bacqué; Laura Idiarte; Marcela Pandolfo; Margarita Angerosa; Mariel Emilce Alejandre; Susana Fraind; Pablo Bresciani; Marco Pizzolato


Acta Bioquimica Clinica Latinoamericana | 2006

Evaluación del perfil tubular renal mediante electroforesis en gel de poliacrilamida

María Laura Facio; Leticia Madalena; Pablo Bresciani; Marcela Pandolfo; Aldana Kairúz; Mariel Emilce Alejandre; Susana Fraind; Margarita Angerosa; Marco Pizzolato


Acta Bioquimica Clinica Latinoamericana | 2000

Determinación de microproteínas urinarias en orinas sin concentrar

María Laura Facio; Leticia Madalena; Gabriel C Bragantini; Susana Fraind; Pablo Bresciani; Marco Pizzolato


Acta Bioquimica Clinica Latinoamericana | 2013

Gammapatía monoclonal de significado incierto: factores de pronóstico, evolución y riesgo

Mariel Emilce Alejandre; Federico Sackmann; Santiago Pavlovsky; Guillermina Remaggi; Miguel A. Pavlovsky; Marcela Pandolfo; Leticia Madalena; Susana Fraind; María Laura Facio; Astrid Pavlovsky; Marco Pizzolato


Acta Bioquimica Clinica Latinoamericana | 2013

Proteinuria: lesión estructural renal y comparación de métodos

Leticia Madalena; Marcela Pandolfo; María Laura Facio; Claudia Garlatti; Mariel Emilce Alejandre; Pablo Bresciani; Margarita Angerosa; Marco Pizzolato


Acta Bioquimica Clinica Latinoamericana | 2004

Excreción de proteínas de bajo peso molecular en pacientes con proteinuria a cadena liviana como marcadoras de disfunción renal

Leticia Madalena; María Laura Facio; Pablo Bresciani; Susana Fraind; Mariel Emilce Alejandre; Marcela Pandolfo; Margarita Angerosa; Jorge E. Toblli; Marco Pizzolato

Collaboration


Dive into the Leticia Madalena's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pablo Bresciani

University of Buenos Aires

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Susana Fraind

University of Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Marco Pizzolato

University of Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Marcela Pandolfo

University of Buenos Aires

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marco Pizzolato

University of Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Santiago Pavlovsky

Academia Nacional de Medicina

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge